EMBC
Embecta Corp.
Company overview
- Market capitalization
- $335.99M
- Employees
- 1,850
- Latest publication
- 2026-09-29
About Embecta Corp.
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Financial statements
Income Quarterly
| Metric | Q3 20262026-06-30 · USD | Q2 20262026-03-31 · USD | Q1 20262025-12-31 · USD | Q4 20252025-09-30 · USD | Q3 20252025-06-30 · USD | Q2 20252025-03-31 · USD | Q1 20252024-12-31 · USD | Q4 20242024-09-30 · USD |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 271,700,000USD | 221,800,000USD | 261,200,000USD | 264,000,000USD | 295,500,000USD | 259,000,000USD | 261,900,000USD | 286,100,000USD |
| Cost Of Revenue | 118,400,000USD | 96,600,000USD | 85,600,000USD | 108,000,000USD | 100,500,000USD | 97,500,000USD | 95,000,000USD | 114,800,000USD |
| Gross Profit | 153,300,000USD | 125,200,000USD | 175,600,000USD | 156,000,000USD | 195,000,000USD | 161,500,000USD | 166,900,000USD | 171,300,000USD |
| Research Development | 5,600,000USD | 9,700,000USD | 300,000USD | 4,600,000USD | 3,800,000USD | 3,700,000USD | 9,500,000USD | 19,800,000USD |
| Selling General Administrative | 78,600,000USD | 76,200,000USD | 77,600,000USD | 86,900,000USD | 84,400,000USD | 79,600,000USD | 81,100,000USD | 87,800,000USD |
| Total Operating Expenses | 104,600,000USD | 82,300,000USD | 78,500,000USD | 91,600,000USD | 88,900,000USD | 83,000,000USD | 90,000,000USD | 137,700,000USD |
| Operating Income | 48,700,000USD | 42,900,000USD | 97,100,000USD | 64,400,000USD | 106,100,000USD | 78,500,000USD | 76,900,000USD | 33,600,000USD |
| Total Other Income Expense Net | -21,100,000USD | -33,400,000USD | -38,200,000USD | -35,400,000USD | -33,900,000USD | -42,700,000USD | -77,600,000USD | -40,600,000USD |
| Income Before Tax | 27,600,000USD | 9,500,000USD | 58,900,000USD | 29,000,000USD | 72,200,000USD | 35,800,000USD | -700,000USD | -7,000,000USD |
| Income Tax Expense | 6,500,000USD | 13,600,000USD | 14,800,000USD | 2,600,000USD | 26,700,000USD | 12,300,000USD | -700,000USD | -21,600,000USD |
| Net Income | 21,100,000USD | -4,100,000USD | 44,100,000USD | 26,400,000USD | 45,500,000USD | 23,500,000USD | -700,000USD | 14,600,000USD |
| Unclassified Operating Expenses | — | -3,600,000USD | — | — | — | — | — | 21,100,000USD |
| Interest Expense | — | 22,600,000USD | 24,100,000USD | 26,100,000USD | 26,600,000USD | 26,700,000USD | 27,900,000USD | 29,000,000USD |
| Net Interest Income | — | -22,600,000USD | -24,100,000USD | -26,100,000USD | -26,600,000USD | -26,700,000USD | -27,900,000USD | -29,000,000USD |
| Tax Provision | — | 13,600,000USD | 14,800,000USD | 2,600,000USD | 26,700,000USD | 12,300,000USD | -700,000USD | -21,600,000USD |
| Net Income From Continuing Ops | — | -4,100,000USD | 44,100,000USD | 26,400,000USD | 45,500,000USD | 23,500,000USD | 0USD | 14,600,000USD |
| Ebit | — | 42,900,000USD | 83,000,000USD | 55,100,000USD | 98,800,000USD | 62,500,000USD | 27,200,000USD | 22,000,000USD |
| Ebitda | — | 55,700,000USD | 95,900,000USD | 70,800,000USD | 110,600,000USD | 74,200,000USD | 39,100,000USD | 34,000,000USD |
| Depreciation And Amortization | — | 12,800,000USD | 12,900,000USD | 15,700,000USD | 11,800,000USD | 11,700,000USD | 11,900,000USD | 12,000,000USD |
| Reconciled Depreciation | — | 12,800,000USD | 12,900,000USD | 5,300,000USD | 11,800,000USD | 11,700,000USD | 11,900,000USD | 5,700,000USD |
| Selling And Marketing Expenses | — | — | — | — | — | — | — | 9,000,000USD |
| Source | 0001872789-26-000033DeterministicFinal | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy |
Income Yearly
| Metric | FY 20252025-09-30 · USD | FY 20242024-09-30 · USD | FY 20232023-09-30 · USD | FY 20222022-09-30 · USD | FY 20212021-09-30 · USD | FY 20202020-09-30 · USD | FY 20192019-09-30 · USD |
|---|---|---|---|---|---|---|---|
| Total Revenue | 1,080,400,000USD | 1,123,100,000USD | 1,120,800,000USD | 1,129,500,000USD | 1,165,000,000USD | 1,085,500,000USD | 1,109,000,000USD |
| Cost Of Revenue | 400,900,000USD | 394,200,000USD | 370,900,000USD | 354,600,000USD | 365,000,000USD | 323,000,000USD | 323,000,000USD |
| Gross Profit | 679,500,000USD | 728,900,000USD | 749,900,000USD | 774,900,000USD | 800,000,000USD | 763,000,000USD | 786,000,000USD |
| Research Development | 21,500,000USD | 78,800,000USD | 85,200,000USD | 65,000,000USD | 63,000,000USD | 61,000,000USD | 62,000,000USD |
| Selling General Administrative | 318,000,000USD | 356,100,000USD | 325,800,000USD | 283,200,000USD | 300,000USD | 300,000USD | 222,000,000USD |
| Unclassified Operating Expenses | 10,700,000USD | 110,800,000USD | 93,799,999USD | 37,000,000USD | 4,700,000USD | — | — |
| Total Operating Expenses | 350,200,000USD | 554,700,000USD | 520,299,999USD | 396,800,000USD | 308,000,000USD | 276,000,000USD | 284,000,000USD |
| Operating Income | 329,300,000USD | 174,200,000USD | 229,600,000USD | 378,100,000USD | 492,000,000USD | 487,000,000USD | 502,000,000USD |
| Interest Expense | 107,300,000USD | 112,300,000USD | 107,000,000USD | 46,200,000USD | 3,000,000USD | 0USD | 2,000,000USD |
| Net Interest Income | -107,300,000USD | -112,300,000USD | -107,000,000USD | -46,200,000USD | 0USD | 0USD | — |
| Income Before Tax | 136,300,000USD | 44,200,000USD | 105,700,000USD | 256,600,000USD | 495,000,000USD | 485,800,000USD | 500,000,000USD |
| Income Tax Expense | 40,900,000USD | -34,100,000USD | 35,300,000USD | 33,000,000USD | 80,000,000USD | 58,200,000USD | 68,000,000USD |
| Tax Provision | 40,900,000USD | -34,100,000USD | 35,300,000USD | 33,000,000USD | 80,000,000USD | 58,000,000USD | 68,000,000USD |
| Net Income | 95,400,000USD | 78,300,000USD | 70,400,000USD | 223,600,000USD | 414,800,000USD | 427,600,000USD | 432,000,000USD |
| Net Income From Continuing Ops | 95,400,000USD | 78,300,000USD | 70,400,000USD | 223,600,000USD | 415,000,000USD | 428,000,000USD | 432,000,000USD |
| Ebit | 243,600,000USD | 156,500,000USD | 212,700,000USD | 302,800,000USD | 495,000,000USD | 486,000,000USD | 500,000,000USD |
| Ebitda | 294,700,000USD | 199,000,000USD | 245,400,000USD | 334,500,000USD | 533,000,000USD | 524,000,000USD | 536,000,000USD |
| Depreciation And Amortization | 51,100,000USD | 42,500,000USD | 32,700,000USD | 31,700,000USD | 38,000,000USD | 38,000,000USD | 36,000,000USD |
| Reconciled Depreciation | 40,700,000USD | 36,200,000USD | 32,600,000USD | 31,700,000USD | 38,000,000USD | 38,000,000USD | 36,000,000USD |
| Total Other Income Expense Net | -193,000,000USD | -130,000,000USD | -123,900,000USD | -121,499,999USD | 3,000,000USD | -1,000,000USD | -2,000,000USD |
| Selling And Marketing Expenses | — | 9,000,000USD | 15,500,000USD | 11,600,000USD | 240,000,000USD | 215,000,000USD | — |
| Non Operating Income Net Other | — | — | — | -6,800,000USD | — | — | — |
| Net Income Applicable To Common Shares | — | — | — | 223,600,000USD | 415,000,000USD | 428,000,000USD | 432,000,000USD |
| Source | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy |
Balance sheet Quarterly
| Metric | Q3 20262026-06-30 · USD | Q2 20262026-03-31 · USD | Q1 20262025-12-31 · USD | Q4 20252025-09-30 · USD | Q3 20252025-06-30 · USD | Q2 20252025-03-31 · USD | Q1 20252024-12-31 · USD | Q4 20242024-09-30 · USD |
|---|---|---|---|---|---|---|---|---|
| Total Assets | 1,265,300,000USD | 1,029,300,000USD | 1,063,700,000USD | 1,090,900,000USD | 1,157,300,000USD | 1,120,200,000USD | 1,149,500,000USD | 1,285,300,000USD |
| Cash And Equivalents | 214,700,000USD | — | — | — | — | — | — | — |
| Total Current Assets | 705,100,000USD | 608,100,000USD | 620,200,000USD | 631,400,000USD | 681,500,000USD | 643,400,000USD | 667,200,000USD | 761,000,000USD |
| Other Current Assets | 90,500,000USD | 83,500,000USD | 74,800,000USD | 78,400,000USD | 78,200,000USD | 62,300,000USD | 67,600,000USD | 74,000,000USD |
| Total Liabilities | 1,878,000,000USD | — | — | — | — | — | — | — |
| Total Current Liabilities | 419,800,000USD | 247,300,000USD | 234,700,000USD | 261,500,000USD | 275,500,000USD | 259,300,000USD | 298,200,000USD | 374,000,000USD |
| Other Current Liabilities | 138,600,000USD | — | — | — | — | — | — | — |
| Total Stockholder Equity | -612,700,000USD | -626,100,000USD | -613,100,000USD | -650,600,000USD | -669,600,000USD | -736,200,000USD | -768,800,000USD | -738,300,000USD |
| Total Equity Including Noncontrolling Interest | -612,700,000USD | — | — | — | — | — | — | — |
| Short Long Term Debt | 139,400,000USD | 9,500,000USD | 9,500,000USD | 9,500,000USD | 9,500,000USD | 9,500,000USD | 9,500,000USD | 9,500,000USD |
| Long Term Debt | 1,315,700,000USD | 1,316,900,000USD | 1,352,900,000USD | 1,388,700,000USD | 1,458,800,000USD | 1,509,100,000USD | 1,534,700,000USD | 1,565,300,000USD |
| Net Receivables | 182,200,000USD | 147,100,000USD | 159,200,000USD | 148,900,000USD | 182,800,000USD | 202,600,000USD | 220,500,000USD | 248,000,000USD |
| Inventory | 214,200,000USD | 192,600,000USD | 181,800,000USD | 178,600,000USD | 189,900,000USD | 169,200,000USD | 169,100,000USD | 171,500,000USD |
| Property Plant Equipment Net | 335,000,000USD | 237,500,000USD | 248,900,000USD | 257,200,000USD | 262,700,000USD | 257,400,000USD | 258,899,999USD | 290,400,000USD |
| Goodwill | 39,900,000USD | — | — | — | — | — | — | — |
| Intangible Assets | 47,500,000USD | 6,500,000USD | 6,700,000USD | 7,000,000USD | 7,300,000USD | 7,600,000USD | 7,900,000USD | 8,100,000USD |
| Accounts Payable | 90,500,000USD | 79,700,000USD | 72,100,000USD | 74,200,000USD | 61,900,000USD | 58,800,000USD | 73,000,000USD | 91,000,000USD |
| Short Term Debt | 6,400,000USD | 13,000,000USD | 13,000,000USD | 16,300,000USD | 12,900,000USD | 12,900,000USD | 12,900,000USD | 12,900,000USD |
| Common Stock | 600,000USD | 600,000USD | 600,000USD | 600,000USD | 600,000USD | 600,000USD | 600,000USD | 600,000USD |
| Retained Earnings | -404,300,000USD | -424,700,000USD | -411,100,000USD | -445,600,000USD | -457,100,000USD | -493,500,000USD | -507,900,000USD | -498,600,000USD |
| Accumulated Other Comprehensive Income | -292,600,000USD | -290,000,000USD | -284,400,000USD | -285,600,000USD | -283,300,000USD | -308,300,000USD | -319,700,000USD | -292,800,000USD |
| Total Liab | — | 1,655,400,000USD | 1,676,800,000USD | 1,741,500,000USD | 1,826,900,000USD | 1,856,400,000USD | 1,918,300,000USD | 2,023,600,000USD |
| Other Current Liab | — | 148,400,000USD | 142,900,000USD | 161,200,000USD | 193,600,000USD | 187,600,000USD | 212,300,000USD | 432,000,000USD |
| Capital Stock | — | 600,000USD | 600,000USD | 0USD | 600,000USD | 600,000USD | 600,000USD | 600,000USD |
| Good Will | — | 21,900,000USD | 15,400,000USD | 15,400,000USD | 15,400,000USD | 15,500,000USD | 15,500,000USD | 15,600,000USD |
| Cash | — | 184,900,000USD | 204,400,000USD | 225,500,000USD | 230,600,000USD | 209,300,000USD | 210,000,000USD | 267,500,000USD |
| Cash And Short Term Investments | — | 184,900,000USD | 204,400,000USD | 225,500,000USD | 230,600,000USD | 209,300,000USD | 210,000,000USD | 267,500,000USD |
| Net Debt | — | 1,172,800,000USD | 1,215,400,000USD | 1,204,800,000USD | 1,270,200,000USD | 1,342,200,000USD | 1,367,400,000USD | 1,340,900,000USD |
| Short Long Term Debt Total | — | 1,357,700,000USD | 1,419,800,000USD | 1,430,300,000USD | 1,500,800,000USD | 1,551,500,000USD | 1,577,400,000USD | 1,608,400,000USD |
| Property Plant Equipment Gross | — | 752,300,000USD | 786,500,000USD | 791,300,000USD | 789,000,000USD | 754,000,000USD | 735,600,000USD | 779,100,000USD |
| Common Stock Shares Outstanding | — | 58,915,000shares | 58,915,000shares | 58,867,000shares | 58,495,000shares | 58,622,000shares | 58,622,000shares | 58,084,000shares |
| Non Current Assets Total | — | 421,200,000USD | 443,500,000USD | 459,500,000USD | 475,800,000USD | 476,800,000USD | 482,300,000USD | 524,300,000USD |
| Non Current Liabilities Total | — | 1,408,100,000USD | 1,442,100,000USD | 1,480,000,000USD | 1,551,400,000USD | 1,597,100,000USD | 1,620,100,000USD | 1,649,600,000USD |
| Non Current Liabilities Other | — | 63,400,000USD | 61,000,000USD | 63,200,000USD | 63,500,000USD | 58,500,000USD | 55,600,000USD | 54,100,000USD |
| Non Currrent Assets Other | — | 161,800,000USD | 172,500,000USD | 179,900,000USD | 190,400,000USD | 196,300,000USD | 200,000,000USD | 210,200,000USD |
| Net Working Capital | — | 360,800,000USD | 385,500,000USD | 369,900,000USD | 406,000,000USD | 384,100,000USD | 369,000,000USD | 387,000,000USD |
| Unclassified Non Current Assets | — | -6,500,000USD | — | — | — | — | — | — |
| Unclassified Current Liabilities | — | -3,300,000USD | -2,800,000USD | — | — | -9,500,000USD | -9,500,000USD | -171,400,000USD |
| Unclassified Non Current Liabilities | — | 27,800,000USD | 28,200,000USD | 28,100,000USD | 29,100,000USD | 29,500,000USD | 29,800,000USD | 30,200,000USD |
| Unclassified Equity | — | 87,400,000USD | 81,200,000USD | 80,000,000USD | 69,600,000USD | 64,400,000USD | 57,600,000USD | 51,900,000USD |
| Current Deferred Revenue | — | — | — | — | — | — | — | -188,600,000USD |
| Source | 0001872789-26-000033DeterministicFinal | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy |
Balance sheet Yearly
| Metric | FY 20252025-09-30 · USD | FY 20242024-09-30 · USD | FY 20232023-09-30 · USD | FY 20222022-09-30 · USD | FY 20212021-09-30 · USD | FY 20202020-09-30 · USD | FY 20192019-09-30 · USD |
|---|---|---|---|---|---|---|---|
| Total Assets | 1,090,900,000USD | 1,285,300,000USD | 1,214,400,000USD | 1,086,400,000USD | 788,000,000USD | 738,000,000USD | 745,000,000USD |
| Intangible Assets | 7,000,000USD | 8,100,000USD | 9,100,000USD | 8,900,000USD | 18,000,000USD | 14,000,000USD | 16,000,000USD |
| Other Current Assets | 78,400,000USD | 74,000,000USD | 252,600,000USD | 187,600,000USD | 23,400,000USD | 13,000,000USD | 20,000,000USD |
| Total Liab | 1,742,100,000USD | 2,023,600,000USD | 2,036,100,000USD | 1,977,800,000USD | 194,000,000USD | 166,000,000USD | 126,000,000USD |
| Total Stockholder Equity | -650,600,000USD | -738,300,000USD | -821,700,000USD | -891,400,000USD | 594,000,000USD | 572,000,000USD | 577,000,000USD |
| Other Current Liab | 174,400,000USD | 243,400,000USD | 213,800,000USD | 219,300,000USD | 109,800,000USD | 87,000,000USD | 79,000,000USD |
| Common Stock | 600,000USD | 600,000USD | 600,000USD | 600,000USD | 865,000,000USD | 834,000,000USD | 855,000,000USD |
| Capital Stock | 0USD | 600,000USD | 600,000USD | 600,000USD | 865,000,000USD | 834,000,000USD | — |
| Retained Earnings | -445,600,000USD | -498,600,000USD | -541,100,000USD | -577,100,000USD | 0USD | — | — |
| Good Will | 15,400,000USD | 15,600,000USD | 15,600,000USD | 15,700,000USD | 16,000,000USD | 16,000,000USD | 16,000,000USD |
| Cash | 225,500,000USD | 267,500,000USD | 326,300,000USD | 330,900,000USD | 0USD | — | — |
| Cash And Short Term Investments | 225,500,000USD | 267,500,000USD | 326,500,000USD | 330,900,000USD | — | — | — |
| Total Current Assets | 631,400,000USD | 761,000,000USD | 749,100,000USD | 664,700,000USD | 292,000,000USD | 235,000,000USD | 248,000,000USD |
| Total Current Liabilities | 261,500,000USD | 374,000,000USD | 353,500,000USD | 301,000,000USD | 164,000,000USD | 137,000,000USD | 126,000,000USD |
| Net Debt | 1,204,800,000USD | 1,340,900,000USD | 1,312,000,000USD | 1,312,900,000USD | 4,000,000USD | 5,000,000USD | — |
| Short Term Debt | 12,900,000USD | 12,900,000USD | 19,000,000USD | 13,100,000USD | 1,000,000USD | 1,000,000USD | — |
| Short Long Term Debt | 9,500,000USD | 9,500,000USD | 9,500,000USD | 9,500,000USD | — | — | — |
| Short Long Term Debt Total | 1,430,300,000USD | 1,608,400,000USD | 1,638,500,000USD | 1,643,800,000USD | 4,000,000USD | 5,000,000USD | — |
| Long Term Debt | 1,388,700,000USD | 1,565,300,000USD | 1,593,900,000USD | 1,598,100,000USD | — | — | — |
| Net Receivables | 148,900,000USD | 248,000,000USD | 17,900,000USD | 23,400,000USD | 150,600,000USD | 120,000,000USD | 127,000,000USD |
| Inventory | 178,600,000USD | 171,500,000USD | 152,100,000USD | 122,800,000USD | 118,000,000USD | 102,000,000USD | 101,000,000USD |
| Accounts Payable | 74,200,000USD | 91,000,000USD | 53,500,000USD | 41,400,000USD | 54,200,000USD | 50,000,000USD | 47,000,000USD |
| Property Plant Equipment Net | 48,500,000USD | 290,400,000USD | 323,200,000USD | 301,600,000USD | 451,000,000USD | 462,000,000USD | 457,000,000USD |
| Property Plant Equipment Gross | 791,300,000USD | 779,100,000USD | 747,900,000USD | 701,600,000USD | 892,000,000USD | 891,000,000USD | — |
| Accumulated Other Comprehensive Income | -285,600,000USD | -292,800,000USD | -309,100,000USD | -324,900,000USD | -271,000,000USD | -262,000,000USD | -278,000,000USD |
| Common Stock Shares Outstanding | 58,915,000shares | 58,326,000shares | 57,758,000shares | 57,055,327shares | 56,804,716shares | 57,000,000shares | 57,000,000shares |
| Non Current Assets Total | 459,500,000USD | 524,300,000USD | 465,300,000USD | 421,700,000USD | 496,000,000USD | 503,000,000USD | 497,000,000USD |
| Non Current Liabilities Total | 1,480,000,000USD | 1,649,600,000USD | 1,682,600,000USD | 1,676,800,000USD | 29,700,000USD | 29,000,000USD | — |
| Non Current Liabilities Other | 63,200,000USD | 54,100,000USD | 57,200,000USD | 46,100,000USD | 30,000,000USD | 29,000,000USD | — |
| Non Currrent Assets Other | 368,400,000USD | 210,200,000USD | 117,400,000USD | 95,500,000USD | 11,000,000USD | 11,000,000USD | 8,000,000USD |
| Net Working Capital | 369,900,000USD | 387,000,000USD | 395,600,000USD | 363,700,000USD | 128,000,000USD | 98,000,000USD | — |
| Unclassified Non Current Assets | 20,200,000USD | — | — | -89,200,000USD | -7,000,000USD | -6,000,000USD | -8,000,000USD |
| Unclassified Current Liabilities | -9,500,000USD | 17,200,000USD | 24,100,000USD | 17,700,000USD | — | — | — |
| Unclassified Non Current Liabilities | 28,100,000USD | 30,200,000USD | 31,500,000USD | -55,300,000USD | -27,300,000USD | -25,000,000USD | — |
| Unclassified Equity | 80,000,000USD | 51,900,000USD | 27,300,000USD | 9,400,000USD | -865,000,000USD | -834,000,000USD | — |
| Current Deferred Revenue | — | — | 33,600,000USD | — | -1,000,000USD | -1,000,000USD | — |
| Deferred Long Term Liab | — | — | — | 46,100,000USD | — | — | — |
| Other Liab | — | — | — | 41,800,000USD | 27,000,000USD | 25,000,000USD | 42,000,000USD |
| Other Assets | — | — | — | 89,200,000USD | 7,000,000USD | 6,000,000USD | 8,000,000USD |
| Net Tangible Assets | — | — | — | -883,400,000USD | 560,000,000USD | 542,000,000USD | 545,000,000USD |
| Source | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy |
Cash flow YTD
| Metric | Q3 20262026-06-30 · USD |
|---|---|
| Depreciation | 31,100,000USD |
| Stock Based Compensation | 15,800,000USD |
| Deferred Income Tax | 12,100,000USD |
| Change To Account Receivables | -20,800,000USD |
| Change To Inventory | -7,300,000USD |
| Change To Liabilities | 1,100,000USD |
| Change In Working Capital | -33,100,000USD |
| Operating Cash Flow | 90,100,000USD |
| Capital Expenditures | -2,200,000USD |
| Other Investing Activities | -118,300,000USD |
| Investing Cash Flow | -120,500,000USD |
| Net Debt Issuance | -78,600,000USD |
| Net Common Stock Issuance | -13,600,000USD |
| Common Dividends Paid | -18,400,000USD |
| Unclassified Financing Cash Flow | 129,900,000USD |
| Financing Cash Flow | 19,300,000USD |
| Effect Of Forex Changes On Cash | 700,000USD |
| Change In Cash | -10,400,000USD |
| End Cash Flow | 218,200,000USD |
| Source | 0001872789-26-000033DeterministicFinal |
Cash flow Quarterly
| Metric | Q2 20262026-03-31 · USD | Q1 20262025-12-31 · USD | Q4 20252025-09-30 · USD | Q3 20252025-06-30 · USD | Q2 20252025-03-31 · USD | Q1 20252024-12-31 · USD | Q4 20242024-09-30 · USD | Q3 20242024-06-30 · USD |
|---|---|---|---|---|---|---|---|---|
| Net Income | -4,099,999USD | 44,100,000USD | 26,400,000USD | 45,500,000USD | 23,500,000USD | -26,300,000USD | 14,600,000USD | 14,700,000USD |
| Depreciation | 12,800,000USD | 10,300,000USD | 15,700,000USD | 11,800,000USD | 6,500,000USD | 11,900,000USD | 5,700,000USD | 11,100,000USD |
| Stock Based Compensation | 5,700,000USD | 5,900,000USD | 9,500,000USD | 5,900,000USD | 7,300,000USD | 8,900,000USD | 6,200,000USD | 6,300,000USD |
| Other Non Cash Items | 8,099,999USD | -5,600,000USD | 12,100,000USD | 2,600,000USD | 7,200,000USD | 12,500,000USD | 8,400,000USD | 1,600,000USD |
| Change To Account Receivables | 11,300,000USD | -12,000,000USD | 32,500,000USD | 8,000,000USD | -2,100,000USD | 5,800,000USD | -18,500,000USD | -49,500,000USD |
| Change To Inventory | -13,900,000USD | -3,500,000USD | 5,200,000USD | -9,300,000USD | 2,500,000USD | -4,500,000USD | 16,300,000USD | -34,800,000USD |
| Change In Working Capital | 7,900,000USD | -40,900,000USD | 24,100,000USD | 9,100,000USD | -16,000,000USD | -40,900,000USD | 19,400,000USD | -32,500,000USD |
| Total Cash From Operating Activities | 31,100,000USD | 17,200,000USD | 84,000,000USD | 81,200,000USD | 31,800,000USD | -5,300,000USD | 26,600,000USD | -2,100,000USD |
| Capital Expenditures | -500,000USD | -600,000USD | -7,300,000USD | -400,000USD | -100,000USD | -1,500,000USD | 0USD | -9,700,000USD |
| Free Cash Flow | 30,600,000USD | 16,600,000USD | 76,700,000USD | 80,800,000USD | 31,700,000USD | -6,800,000USD | 26,600,000USD | -11,800,000USD |
| Total Cashflows From Investing Activities | -500,000USD | 9,500,000USD | -7,300,000USD | -400,000USD | -100,000USD | -1,500,000USD | — | -9,700,000USD |
| Net Borrowings | -37,900,000USD | -37,900,000USD | -72,800,000USD | -52,800,000USD | -27,700,000USD | -32,700,000USD | -27,700,000USD | — |
| Total Cash From Financing Activities | -41,500,000USD | -51,600,000USD | -81,600,000USD | -62,600,000USD | -37,300,000USD | -45,200,000USD | -36,600,000USD | -11,500,000USD |
| Dividends Paid | -8,900,000USD | -8,900,000USD | -8,800,000USD | -8,700,000USD | -8,700,000USD | -8,800,000USD | -8,700,000USD | -8,600,000USD |
| Change In Cash | -11,000,000USD | -24,200,000USD | -5,000,000USD | 21,300,000USD | -4,400,000USD | -57,500,000USD | -7,600,000USD | -24,700,000USD |
| Begin Period Cash Flow | 204,400,000USD | 228,600,000USD | 233,600,000USD | 212,300,000USD | 216,700,000USD | 274,200,000USD | 281,800,000USD | 306,500,000USD |
| End Period Cash Flow | 193,400,000USD | 204,400,000USD | 228,600,000USD | 233,600,000USD | 212,300,000USD | 216,700,000USD | 274,200,000USD | 281,800,000USD |
| Other Cashflows From Financing Activities | 5,300,000USD | — | -5,700,000USD | -1,100,000USD | -28,300,000USD | -3,700,000USD | -200,000USD | -100,000USD |
| Sale Purchase Of Stock | — | -4,800,000USD | 5,700,000USD | -1,100,000USD | -900,000USD | -3,700,000USD | -200,000USD | -100,000USD |
| Other Cashflows From Investing Activities | — | 10,100,000USD | — | — | — | — | — | — |
| Unclassified Operating Cash Flow | — | 3,400,000USD | -3,800,000USD | 6,300,000USD | 3,300,000USD | 28,600,000USD | -27,700,000USD | -3,300,000USD |
| Investments | — | — | -7,300,000USD | -400,000USD | -100,000USD | -1,500,000USD | 0USD | -9,700,000USD |
| Unclassified Investing Cash Flow | — | — | 7,300,000USD | — | — | 1,500,000USD | — | 9,700,000USD |
| Unclassified Financing Cash Flow | — | — | — | 1,100,000USD | 28,300,000USD | 3,700,000USD | — | -2,700,000USD |
| Source | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy |
Cash flow Yearly
| Metric | FY 20252025-09-30 · USD | FY 20242024-09-30 · USD | FY 20232023-09-30 · USD | FY 20222022-09-30 · USD | FY 20212021-09-30 · USD | FY 20202020-09-30 · USD | FY 20192019-09-30 · USD |
|---|---|---|---|---|---|---|---|
| Net Income | 95,400,000USD | 78,300,000USD | 70,400,000USD | 223,600,000USD | 415,000,000USD | 427,600,000USD | 432,000,000USD |
| Depreciation | 40,700,000USD | 36,200,000USD | 32,600,000USD | 31,700,000USD | 38,000,000USD | 38,300,000USD | 36,000,000USD |
| Stock Based Compensation | 31,600,000USD | 26,300,000USD | 21,500,000USD | 18,700,000USD | 12,800,000USD | 12,700,000USD | 12,000,000USD |
| Other Non Cash Items | 30,100,000USD | 13,200,000USD | 8,900,000USD | 72,300,000USD | 24,200,000USD | 9,400,000USD | 9,000,000USD |
| Change To Account Receivables | 44,200,000USD | -174,700,000USD | 7,000,000USD | 122,700,000USD | -32,000,000USD | -2,400,000USD | -10,000,000USD |
| Change To Inventory | -6,100,000USD | -16,500,000USD | -28,800,000USD | -23,400,000USD | -18,000,000USD | 3,500,000USD | 9,000,000USD |
| Change In Working Capital | -23,700,000USD | -47,700,000USD | -80,000,000USD | 92,400,000USD | -32,000,000USD | 12,700,000USD | 22,000,000USD |
| Total Cash From Operating Activities | 191,700,000USD | 35,700,000USD | 67,700,000USD | 412,200,000USD | 456,000,000USD | 498,500,000USD | 505,000,000USD |
| Capital Expenditures | -9,300,000USD | -15,800,000USD | -26,500,000USD | -24,000,000USD | -39,000,000USD | -41,900,000USD | -69,000,000USD |
| Free Cash Flow | 182,400,000USD | 19,900,000USD | 41,200,000USD | 388,200,000USD | 417,000,000USD | 456,600,000USD | 436,000,000USD |
| Investments | -9,300,000USD | -15,800,000USD | -26,500,000USD | -24,000,000USD | -39,000,000USD | -42,000,000USD | -69,000,000USD |
| Total Cashflows From Investing Activities | -9,300,000USD | -15,800,000USD | -26,500,000USD | -24,000,000USD | -39,000,000USD | -41,900,000USD | -69,000,000USD |
| Net Borrowings | -186,000,000USD | -35,900,000USD | -10,700,000USD | 1,411,900,000USD | 1,443,400,000USD | 1,443,400,000USD | 1,443,400,000USD |
| Total Cash From Financing Activities | -226,700,000USD | -73,400,000USD | -48,700,000USD | -48,000,000USD | -417,000,000USD | -456,600,000USD | -436,000,000USD |
| Dividends Paid | -35,000,000USD | -34,500,000USD | -34,400,000USD | -8,600,000USD | -8,600,000USD | -8,600,000USD | -8,600,000USD |
| Sale Purchase Of Stock | -5,700,000USD | -3,000,000USD | -3,600,000USD | — | — | — | — |
| Change In Cash | -45,600,000USD | -52,300,000USD | -4,400,000USD | 330,900,000USD | -417,000,000USD | -457,000,000USD | -436,000,000USD |
| Begin Period Cash Flow | 274,200,000USD | 326,500,000USD | 330,900,000USD | 264,300,000USD | 0USD | 0USD | 0USD |
| End Period Cash Flow | 228,600,000USD | 274,200,000USD | 326,500,000USD | 330,900,000USD | 264,300,000USD | 0USD | 0USD |
| Other Cashflows From Financing Activities | -5,700,000USD | -3,000,000USD | -3,600,000USD | -32,800,000USD | -417,000,000USD | -456,600,000USD | -436,000,000USD |
| Unclassified Operating Cash Flow | 17,600,000USD | -70,600,000USD | 14,300,000USD | -26,500,000USD | — | — | -6,000,000USD |
| Unclassified Investing Cash Flow | 9,300,000USD | 15,800,000USD | 26,500,000USD | 24,400,000USD | 41,400,000USD | 42,000,000USD | 72,000,000USD |
| Unclassified Financing Cash Flow | 5,700,000USD | 3,000,000USD | 3,600,000USD | -1,418,500,000USD | -1,434,800,000USD | -1,434,800,000USD | -1,434,800,000USD |
| Change To Liabilities | — | — | — | 83,600,000USD | 30,000,000USD | -4,000,000USD | 32,000,000USD |
| Cash And Cash Equivalents Changes | — | — | — | 340,200,000USD | — | — | — |
| Other Cashflows From Investing Activities | — | — | — | -400,000USD | -2,400,000USD | — | -3,000,000USD |
| Source | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy |
Operating metrics
No operating metrics are currently published for this company.
Revenue breakdown
| Period | Dimension | Business / region | Revenue | Currency | Source |
|---|---|---|---|---|---|
| Q2 2026Quarterly · 2026-03-31 | Geography | International | 126,400,000 | USD | 0001872789-26-000017 |
| Q2 2026Quarterly · 2026-03-31 | Geography | United States | 95,400,000 | USD | 0001872789-26-000017 |
| Q2 2026Quarterly · 2026-03-31 | Product | Manufacturing Facility | 2,500,000 | USD | 0001872789-26-000017 |
| Q2 2026Quarterly · 2026-03-31 | Product | Pen Needles | 154,700,000 | USD | 0001872789-26-000017 |
| Q2 2026Quarterly · 2026-03-31 | Product | Product And Service Other | 4,000,000 | USD | 0001872789-26-000017 |
| Q2 2026Quarterly · 2026-03-31 | Product | Safety | 34,300,000 | USD | 0001872789-26-000017 |
| Q2 2026Quarterly · 2026-03-31 | Product | Syringes | 26,300,000 | USD | 0001872789-26-000017 |
| Q1 2026Quarterly · 2025-12-31 | Geography | International | 130,300,000 | USD | 0001872789-26-000009 |
| Q1 2026Quarterly · 2025-12-31 | Geography | United States | 130,900,000 | USD | 0001872789-26-000009 |
| Q1 2026Quarterly · 2025-12-31 | Product | Manufacturing Facility | 4,100,000 | USD | 0001872789-26-000009 |
| Q1 2026Quarterly · 2025-12-31 | Product | Pen Needles | 185,500,000 | USD | 0001872789-26-000009 |
| Q1 2026Quarterly · 2025-12-31 | Product | Product And Service Other | 3,600,000 | USD | 0001872789-26-000009 |
| Q1 2026Quarterly · 2025-12-31 | Product | Safety | 37,300,000 | USD | 0001872789-26-000009 |
| Q1 2026Quarterly · 2025-12-31 | Product | Syringes | 30,700,000 | USD | 0001872789-26-000009 |
| Q4 2025Quarterly · 2025-09-30 | Geography | International | 122,000,000 | USD | Legacy provider |
| Q4 2025Quarterly · 2025-09-30 | Geography | United States | 142,000,000 | USD | Legacy provider |
| Q4 2025Quarterly · 2025-09-30 | Product | Manufacturing Facility | 5,200,000 | USD | Legacy provider |
| Q4 2025Quarterly · 2025-09-30 | Product | Pen Needles | 187,800,000 | USD | Legacy provider |
| Q4 2025Quarterly · 2025-09-30 | Product | Product And Service Other | 4,100,000 | USD | Legacy provider |
| Q4 2025Quarterly · 2025-09-30 | Product | Safety | 34,600,000 | USD | Legacy provider |
| Q4 2025Quarterly · 2025-09-30 | Product | Syringes | 32,300,000 | USD | Legacy provider |
| FY 2025Yearly · 2025-09-30 | Geography | International | 501,300,000 | USD | 0001872789-25-000036 |
| FY 2025Yearly · 2025-09-30 | Geography | United States | 579,100,000 | USD | 0001872789-25-000036 |
| FY 2025Yearly · 2025-09-30 | Product | Manufacturing Facility | 19,900,000 | USD | 0001872789-25-000036 |
| FY 2025Yearly · 2025-09-30 | Product | Pen Needles | 784,100,000 | USD | 0001872789-25-000036 |
| FY 2025Yearly · 2025-09-30 | Product | Product And Service Other | 14,000,000 | USD | 0001872789-25-000036 |
| FY 2025Yearly · 2025-09-30 | Product | Safety | 137,800,000 | USD | 0001872789-25-000036 |
| FY 2025Yearly · 2025-09-30 | Product | Syringes | 124,600,000 | USD | 0001872789-25-000036 |
| Q3 2025Quarterly · 2025-06-30 | Geography | International | 135,300,000 | USD | 0001872789-25-000029 |
| Q3 2025Quarterly · 2025-06-30 | Geography | United States | 160,200,000 | USD | 0001872789-25-000029 |
| Q3 2025Quarterly · 2025-06-30 | Product | Manufacturing Facility | 5,500,000 | USD | 0001872789-25-000029 |
| Q3 2025Quarterly · 2025-06-30 | Product | Pen Needles | 216,900,000 | USD | 0001872789-25-000029 |
| Q3 2025Quarterly · 2025-06-30 | Product | Product And Service Other | 3,200,000 | USD | 0001872789-25-000029 |
| Q3 2025Quarterly · 2025-06-30 | Product | Safety | 34,800,000 | USD | 0001872789-25-000029 |
| Q3 2025Quarterly · 2025-06-30 | Product | Syringes | 35,100,000 | USD | 0001872789-25-000029 |
| Q2 2025Quarterly · 2025-03-31 | Geography | International | 123,800,000 | USD | 0001872789-26-000017 |
| Q2 2025Quarterly · 2025-03-31 | Geography | United States | 135,200,000 | USD | 0001872789-26-000017 |
| Q2 2025Quarterly · 2025-03-31 | Product | Manufacturing Facility | 4,400,000 | USD | 0001872789-26-000017 |
| Q2 2025Quarterly · 2025-03-31 | Product | Pen Needles | 188,300,000 | USD | 0001872789-26-000017 |
| Q2 2025Quarterly · 2025-03-31 | Product | Product And Service Other | 3,300,000 | USD | 0001872789-26-000017 |
| Q2 2025Quarterly · 2025-03-31 | Product | Safety | 34,200,000 | USD | 0001872789-26-000017 |
| Q2 2025Quarterly · 2025-03-31 | Product | Syringes | 28,800,000 | USD | 0001872789-26-000017 |
| Q1 2025Quarterly · 2024-12-31 | Geography | International | 120,200,000 | USD | 0001872789-26-000009 |
| Q1 2025Quarterly · 2024-12-31 | Geography | United States | 141,700,000 | USD | 0001872789-26-000009 |
| Q1 2025Quarterly · 2024-12-31 | Product | Manufacturing Facility | 4,800,000 | USD | 0001872789-26-000009 |
| Q1 2025Quarterly · 2024-12-31 | Product | Pen Needles | 191,100,000 | USD | 0001872789-26-000009 |
| Q1 2025Quarterly · 2024-12-31 | Product | Product And Service Other | 3,400,000 | USD | 0001872789-26-000009 |
| Q1 2025Quarterly · 2024-12-31 | Product | Safety | 34,200,000 | USD | 0001872789-26-000009 |
| Q1 2025Quarterly · 2024-12-31 | Product | Syringes | 28,400,000 | USD | 0001872789-26-000009 |
| Q4 2024Quarterly · 2024-09-30 | Geography | International | 118,700,000 | USD | Legacy provider |
| Q4 2024Quarterly · 2024-09-30 | Geography | United States | 167,400,000 | USD | Legacy provider |
| Q4 2024Quarterly · 2024-09-30 | Product | Manufacturing Facility | 4,700,000 | USD | Legacy provider |
| Q4 2024Quarterly · 2024-09-30 | Product | Pen Needles | 215,100,000 | USD | Legacy provider |
| Q4 2024Quarterly · 2024-09-30 | Product | Product And Service Other | 0 | USD | Legacy provider |
| Q4 2024Quarterly · 2024-09-30 | Product | Safety | 32,900,000 | USD | Legacy provider |
| Q4 2024Quarterly · 2024-09-30 | Product | Syringes | 33,700,000 | USD | Legacy provider |
| FY 2024Yearly · 2024-09-30 | Geography | International | 515,900,000 | USD | 0001872789-25-000036 |
| FY 2024Yearly · 2024-09-30 | Geography | United States | 607,200,000 | USD | 0001872789-25-000036 |
| FY 2024Yearly · 2024-09-30 | Product | Manufacturing Facility | 12,800,000 | USD | 0001872789-25-000036 |
| FY 2024Yearly · 2024-09-30 | Product | Pen Needles | 844,400,000 | USD | 0001872789-25-000036 |
| FY 2024Yearly · 2024-09-30 | Product | Product And Service Other | 10,300,000 | USD | 0001872789-25-000036 |
| FY 2024Yearly · 2024-09-30 | Product | Safety | 129,400,000 | USD | 0001872789-25-000036 |
| FY 2024Yearly · 2024-09-30 | Product | Syringes | 126,200,000 | USD | 0001872789-25-000036 |
| Q3 2024Quarterly · 2024-06-30 | Geography | International | 128,900,000 | USD | 0001872789-25-000029 |
| Q3 2024Quarterly · 2024-06-30 | Geography | United States | 143,600,000 | USD | 0001872789-25-000029 |
| Q3 2024Quarterly · 2024-06-30 | Product | Manufacturing Facility | 3,600,000 | USD | 0001872789-25-000029 |
| Q3 2024Quarterly · 2024-06-30 | Product | Pen Needles | 201,300,000 | USD | 0001872789-25-000029 |
| Q3 2024Quarterly · 2024-06-30 | Product | Product And Service Other | 3,500,000 | USD | 0001872789-25-000029 |
| Q3 2024Quarterly · 2024-06-30 | Product | Safety | 32,400,000 | USD | 0001872789-25-000029 |
| Q3 2024Quarterly · 2024-06-30 | Product | Syringes | 31,700,000 | USD | 0001872789-25-000029 |
| FY 2023Yearly · 2023-09-30 | Geography | International | 519,400,000 | USD | 0001872789-25-000036 |
| FY 2023Yearly · 2023-09-30 | Geography | United States | 601,400,000 | USD | 0001872789-25-000036 |
| FY 2023Yearly · 2023-09-30 | Product | Manufacturing Facility | 13,000,000 | USD | 0001872789-25-000036 |
| FY 2023Yearly · 2023-09-30 | Product | Pen Needles | 829,200,000 | USD | 0001872789-25-000036 |
| FY 2023Yearly · 2023-09-30 | Product | Product And Service Other | 14,200,000 | USD | 0001872789-25-000036 |
| FY 2023Yearly · 2023-09-30 | Product | Safety | 126,300,000 | USD | 0001872789-25-000036 |
| FY 2023Yearly · 2023-09-30 | Product | Syringes | 138,100,000 | USD | 0001872789-25-000036 |
| FY 2022Yearly · 2022-09-30 | Geography | International | 529,200,000 | USD | 0001872789-24-000037 |
| FY 2022Yearly · 2022-09-30 | Geography | United States | 600,300,000 | USD | 0001872789-24-000037 |
| FY 2022Yearly · 2022-09-30 | Product | Manufacturing Facility | 15,000,000 | USD | 0001872789-24-000037 |
| FY 2022Yearly · 2022-09-30 | Product | Pen Needles | 824,600,000 | USD | 0001872789-24-000037 |
| FY 2022Yearly · 2022-09-30 | Product | Product And Service Other | 14,300,000 | USD | 0001872789-24-000037 |
| FY 2022Yearly · 2022-09-30 | Product | Safety | 119,600,000 | USD | 0001872789-24-000037 |
| FY 2022Yearly · 2022-09-30 | Product | Syringes | 156,000,000 | USD | 0001872789-24-000037 |
| FY 2021Yearly · 2021-09-30 | Geography | International | 555,900,000 | USD | 0001872789-23-000031 |
| FY 2021Yearly · 2021-09-30 | Geography | United States | 609,400,000 | USD | 0001872789-23-000031 |
| FY 2020Yearly · 2020-09-30 | Geography | International | 522,500,000 | USD | 0001872789-22-000024 |
| FY 2020Yearly · 2020-09-30 | Geography | United States | 563,000,000 | USD | 0001872789-22-000024 |
Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.